Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-29

Dyne Therapeutics, Inc. (DYN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,695,986
Erick Lucera total, FY2025
Chief Financial Officer and Treasurerhighest-paid officer; CEO John Cox: $2,076,868
1st
CEO (John Cox) pay percentile vs peers
6:1
CEO-to-median pay ratio
99.14%
Say-on-pay support, latest vote
Companies that benchmark against DYN
9 companies name DYN as a compensation peer

Each company listed discloses DYN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DYN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Erick Lucera$391,970$0$691,406$1,408,214$197,600$0$6,796$2,695,986
Chief Financial Officer and Treasurer
John Cox721,00000937,893410,97007,0052,076,868
President and Chief Executive Officer
Johanna Friedl-Naderer610,69100243,666232,063001,086,420
Chief Commercial Officer
Douglas Kerr537,00000309,533204,06007,0051,057,598
Chief Medical Officer
Oxana Beskrovnaya531,50000252,153201,97007,005992,628
Chief Innovation Officer; Former Chief Scientific Officer
Richard Scalzo107,5000166,773106,33500347,030727,638
Former Senior Vice President, Head of Finance and Administration

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Erick Lucera$2,695,986
John Cox2,076,86820,688,724−18,611,856
Johanna Friedl-Naderer1,086,4208,190,480−7,104,060
Douglas Kerr1,057,5987,741,647−6,684,049
Oxana Beskrovnaya992,6283,835,6501,997,845−2,843,022
Richard Scalzo727,6382,485,672−1,758,034

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jason RhodesDirector2026-04-23D894$18$16,226CommonForm 4 ↗
Jason RhodesDirector2026-04-23D45,70918829,618CommonForm 4 ↗
Jason RhodesDirector2026-04-23D90,943181,650,615CommonForm 4 ↗
Jason RhodesDirector2026-04-23D19,26119369,619CommonForm 4 ↗
Jason RhodesDirector2026-04-23D38,32219735,399CommonForm 4 ↗
Jason RhodesDirector2026-04-23D377197,235CommonForm 4 ↗
Jason RhodesDirector2026-04-23D35,94718652,438CommonForm 4 ↗
Jason RhodesDirector2026-04-23D72,310181,336,289CommonForm 4 ↗
Jason RhodesDirector2026-04-23D28,58318528,214CommonForm 4 ↗
Jason RhodesDirector2026-04-23D15,14819290,690CommonForm 4 ↗
Jason RhodesDirector2026-04-23D36,34518671,656CommonForm 4 ↗
Jason RhodesDirector2026-04-23D7101813,121CommonForm 4 ↗
David LubnerDirector2026-04-24D53,62500CommonForm 4 ↗
Jason RhodesDirector2026-04-28D47,08218865,367CommonForm 4 ↗
Jason RhodesDirector2026-04-28D59,870181,100,411CommonForm 4 ↗
Jason RhodesDirector2026-04-28D1,1701821,505CommonForm 4 ↗
Jason RhodesDirector2026-04-28D11919CommonForm 4 ↗
Jason RhodesDirector2026-04-28D2119399CommonForm 4 ↗
Jason RhodesDirector2026-04-28D5219988CommonForm 4 ↗
Jason RhodesDirector2026-04-28D2619494CommonForm 4 ↗
Jason RhodesDirector2026-04-28D119,115182,189,334CommonForm 4 ↗
Jason RhodesDirector2026-05-04D2,4031843,326CommonForm 4 ↗
Jason RhodesDirector2026-05-04D2,4661844,388CommonForm 4 ↗
Jason RhodesDirector2026-05-04D3,0561855,100CommonForm 4 ↗
Jason RhodesDirector2026-05-04D6,24118112,338CommonForm 4 ↗
Jason RhodesDirector2026-05-04D21,92618398,615CommonForm 4 ↗
Jason RhodesDirector2026-05-04D61181,098CommonForm 4 ↗
Jason RhodesDirector2026-05-04D60181,082CommonForm 4 ↗
Jason RhodesDirector2026-05-04D6,08118109,640CommonForm 4 ↗
Jason RhodesDirector2026-05-04D3,1361856,448CommonForm 4 ↗
Jason RhodesDirector2026-05-04D17,24418313,496CommonForm 4 ↗
Jason RhodesDirector2026-05-04D43,62118793,030CommonForm 4 ↗
Jason RhodesDirector2026-05-04D428187,781CommonForm 4 ↗
John CoxDirector2026-05-13D3,3111860,790CommonForm 4 ↗
Erick LuceraChief Financial Officer2026-05-13D1,4481826,585CommonForm 4 ↗
Johanna Friedl-NadererChief Commercial Officer2026-05-13D228184,186CommonForm 4 ↗
Douglas KerrChief Medical Officer2026-05-13D1,5641828,715CommonForm 4 ↗
Brian S. PosnerDirector2026-05-20A2,5001742,800CommonForm 4 ↗
Brian S. PosnerDirector2026-05-26A2,0001836,420CommonForm 4 ↗
Brian S. PosnerDirector2026-06-03A2,5001743,700CommonForm 4 ↗
Dirk KerstenDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Edward HurwitzDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Brian S. PosnerDirector2026-06-05A2,0001733,880CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Carlo IncertiDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Brian S. PosnerDirector2026-06-05A35,15200Derivative, Class A CommonForm 4 ↗
Douglas KerrChief Medical Officer2026-06-16D8871816,259CommonForm 4 ↗
Johanna Friedl-NadererChief Commercial Officer2026-06-16D145182,658CommonForm 4 ↗
John CoxDirector2026-06-16D2,6831849,179CommonForm 4 ↗
Dirk KerstenDirector2026-06-17D37,45420754,316Common, indirectForm 4 ↗
Dirk KerstenDirector2026-06-17D46,90120941,373Common, indirectForm 4 ↗
Dirk KerstenDirector2026-06-22D1,6572135,583Common, indirectForm 4 ↗
Barry E. GreeneDirector2026-06-22A57,46300Derivative, Class A CommonForm 4 ↗
Dirk KerstenDirector2026-06-22D190,676213,922,263Common, indirectForm 4 ↗
Dirk KerstenDirector2026-06-22D71,629211,506,766Common, indirectForm 4 ↗
Jason RhodesDirector2026-06-23D50,530211,062,141CommonForm 4 ↗
Jason RhodesDirector2026-06-23D77,855211,645,076CommonForm 4 ↗
Jason RhodesDirector2026-06-23D30,77421650,255CommonForm 4 ↗
Jason RhodesDirector2026-06-23D12,69921267,949CommonForm 4 ↗
Jason RhodesDirector2026-06-23D39,13121826,838CommonForm 4 ↗
Jason RhodesDirector2026-06-23D5,01921105,901CommonForm 4 ↗
Jason RhodesDirector2026-06-23D19,97321419,832CommonForm 4 ↗
Jason RhodesDirector2026-06-23D25,39721533,845CommonForm 4 ↗
Jason RhodesDirector2026-06-23D6,38221134,660CommonForm 4 ↗
Erick LuceraChief Financial Officer2026-06-25D2,3622048,114CommonForm 4 ↗
Jason RhodesDirector2026-06-26D64,411211,370,666CommonForm 4 ↗
Jason RhodesDirector2026-06-26D102,969212,176,765CommonForm 4 ↗
Jason RhodesDirector2026-06-26D51,756211,094,122CommonForm 4 ↗
Jason RhodesDirector2026-06-26D162,954213,467,661CommonForm 4 ↗
Jason RhodesDirector2026-06-26D40,70221860,440CommonForm 4 ↗
Jason RhodesDirector2026-06-26D81,903211,742,896CommonForm 4 ↗
Jason RhodesDirector2026-07-06D127,182232,898,478CommonForm 4 ↗
Jason RhodesDirector2026-07-06D11,66524275,527CommonForm 4 ↗
Jason RhodesDirector2026-07-06D100,019232,279,433CommonForm 4 ↗
Jason RhodesDirector2026-07-06D14,84424350,615CommonForm 4 ↗
Jason RhodesDirector2026-07-06D253,039235,766,759CommonForm 4 ↗
Jason RhodesDirector2026-07-06D124,379232,881,861CommonForm 4 ↗
Jason RhodesDirector2026-07-06D29,58724698,845CommonForm 4 ↗
Jason RhodesDirector2026-07-06D5,00024118,050CommonForm 4 ↗
Jason RhodesDirector2026-07-06D49,193231,139,802CommonForm 4 ↗
Jason RhodesDirector2026-07-06D62,543231,449,121CommonForm 4 ↗
Dirk KerstenDirector2026-07-27D5,38826140,319Common, indirectForm 4 ↗
Dirk KerstenDirector2026-07-27D256,072266,530,451Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Erick LuceraRSU2025-03-3166,100$691,406
Johanna Friedl-NadererOPTION2025-07-1651,255243,666
Oxana BeskrovnayaOPTION2025-07-1653,040252,153
John CoxOPTION2025-07-16197,285937,893
Erick LuceraOPTION2025-03-31214,5001,408,214
Douglas KerrOPTION2025-07-1665,110309,533
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Erick Lucera$691,406$0$1,408,2140.0%
Johanna Friedl-Naderer00243,6660.0%
Oxana Beskrovnaya00252,1530.0%
John Cox00937,8930.0%
Douglas Kerr00309,5330.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
John CoxOption197,2859.33
John CoxRSU108,9762,131,571
Oxana BeskrovnayaRSU46,862916,621
Oxana BeskrovnayaRSU29,328573,656
Oxana BeskrovnayaRSU10,000195,600
John CoxOption174,07529.44
Erick LuceraOption214,50010.46
Oxana BeskrovnayaOption53,0409.33
Oxana BeskrovnayaOption17,48710.88
Douglas KerrOption103,33131.94
Oxana BeskrovnayaOption15,75010.72
Johanna Friedl-NadererOption127,39431.94
Oxana BeskrovnayaOption46,80029.44
John CoxOption382,41726.06
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation committee has developed and administers our executive compensation program with these considerations in mind to deliver incentives that balance our retention and motivation objectives while rewarding executives for realization of long-term objectives and our ability to create sustained value for our stockholders and the execution of strategic annual goals that are critical to the execution of our business plan.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-05147,732,1421,279,30261,51499.14%Passed
20252025-05-3074,412,45315,817,10281,55582.47%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0599.14%a
20252025-05-3082.47%b

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)6 : 1
CEO total compensation$2,076,868
Median employee compensation$338,650
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Vikram KarnaniIndependent · Compensation · Newly elected$0$798,986$0$0$798,986
Brian S. PosnerIndependent · Audit · Compensation · Newly elected11,2500559,90900571,159
Jason RhodesIndependent · Board Chair · Nominating/Governance (Chair)90,0000264,50600354,506
Dirk KerstenIndependent · Audit · Compensation (Chair)70,0000264,50600334,506
David LubnerIndependent · Audit (Chair) · Nominating/Governance70,0000264,50600334,506
Catherine Stehman-Breen, M.DIndependent · Audit · Compensation · Research and Development62,5000264,50600327,006
Edward HurwitzIndependent · Compensation52,5000264,50600317,006
Carlo Incerti, M.DIndependent · Research and Development52,5000264,50600317,006
John G. CoxEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$264,506
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 7,500 / 5,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$408,750
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$408,750

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Dyne Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Dyne Therapeutics, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Arcellx2024Rami Elghandour$653,288$9,342,069$10,850,151$0$21,402,668
2Immunovant2026Eric Venker636,618019,010,639020,158,767
3BridgeBio Pharma2025Neil Kumar1,044,00010,606,2751,874,992014,944,585
4Revolution Medicines2025Mark Goldsmith812,5003,968,0768,995,114889,70014,672,390
5Cytokinetics2025Robert Blum853,0695,150,0195,095,918772,71511,881,456
6Crinetics Pharmaceuticals2025R. Scott Struthers718,5003,280,5407,160,564462,35511,628,959
7Nuvalent2025James Porter652,1004,392,5635,857,906469,51211,393,602
8IDEAYA Biosciences2025Yujiro Hata700,00008,418,840378,0009,512,640
9Xenon Pharmaceuticals2025Ian Mortimer786,0001,774,0006,065,255550,2009,221,712
10Kymera Therapeutics2025Nello Mainolfi693,00007,318,859519,7508,545,609
11CRISPR Therapeutics AG2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
12Arvinas2025John Houston706,2362,685,8402,671,051457,0006,534,127
13Beam Therapeutics2025John Evans755,0001,513,5752,876,754662,5135,818,525
14Celldex Therapeutics2025Anthony Marucci785,80404,027,59005,366,709
15Intellia Therapeutics2025John Leonard708,0002,443,9201,356,32005,063,899
16Denali Therapeutics2025Ryan Watts718,0001,151,8672,180,00304,751,515
17Rocket Pharmaceuticals2025Gaurav Shah671,076806,7511,613,377403,0483,510,241
18Keros Therapeutics2025Jasbir Seehra700,0001,426,2800398,1252,540,204
19Dyne Therapeutics, Inc.2025John Cox721,0000937,893410,9702,076,868

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Dyne Therapeutics, Inc.95%not disclosednot disclosedAlpine Rewards, LLC
Arcellx140%not disclosedNoMeridian Compensation Partners, LLC
Arvinas108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Beam Therapeutics135%Options 66 · RSU 34not disclosedPay Governance LLC
BridgeBio Pharma135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Celldex Therapeutics100%Options 100not disclosedAon (Human Capital Solutions practice, a division of Aon plc)
Crinetics Pharmaceuticalsnot disclosedOptions 70 · RSU 30not disclosedPearl Meyer
CRISPR Therapeutics AG122.5%not disclosednot disclosedAlpine Rewards, LLC
Cytokinetics120%RSU 50 · Options 50not disclosedAon Human Capital Solutions
Denali Therapeutics145%not disclosednot disclosedAlpine Rewards
IDEAYA Biosciences90%Options 100not disclosedAon (Aon plc, Talent Solutions practice)
Immunovant110%not disclosedNoCompensia
Intellia Therapeutics115%Options 40 · RSU 40 · PSU 20Yes — TSR relative to the Nasdaq Biotechnology IndexAlpine Rewards, LLC
Keros Therapeutics87.5%RSU 50 · PSU 50NoAon (Human Capital Solutions practice)
Kymera Therapeutics125%not disclosedNoAlpine Rewards
Nuvalent120%not disclosedNoAlpine Rewards
Revolution Medicines146%Options 70 · RSU 30not disclosedCompensia
Rocket Pharmaceuticalsnot disclosednot disclosednot disclosedSemler Brossy
Xenon Pharmaceuticals100%not disclosedNoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Dyne Therapeutics, Inc. in fiscal 2025?
The highest-paid executive at Dyne Therapeutics, Inc. in fiscal 2025 was Erick Lucera, Chief Financial Officer and Treasurer, with total compensation of $2,695,986.
How does Dyne Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
The company reported that the CEO's pay was in the 1st percentile of the disclosed peer group.
What is Dyne Therapeutics, Inc.'s CEO-to-median employee pay ratio?
The CEO-to-median employee pay ratio was 6:1 as disclosed in the filing.
How did shareholders vote on Dyne Therapeutics, Inc.'s executive compensation?
Shareholders voted 99.14% in support of the executive compensation plan in the latest vote.
How much does Dyne Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
Total board compensation for fiscal 2025 was $408,750.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Erick LuceraDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 2,695,986. Filing ↗machine: r5 · c24 · span 836224–836233
2Section 01, John CoxDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248
3Section 01, Johanna Friedl-NadererDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 1,086,420. Filing ↗machine: r7 · c25 · span 853791–853800
4Section 01, Douglas KerrDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 1,057,598. Filing ↗machine: r9 · c24 · span 873746–873755
5Section 01, Oxana BeskrovnayaDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 992,628. Filing ↗machine: r13 · c24 · span 913684–913691
6Section 01, Richard ScalzoDEF 14A2026-04-230001193125-26-173655Section “Summary Compensation Table” · page 36. As printed: 727,638. Filing ↗machine: r11 · c24 · span 893718–893725
7Section 03, Erick Lucera RSUDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r5 · c9 · span 830409–830416
8Section 03, Johanna Friedl-Naderer OPTIONDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r10 · c32 · span 1069347–1069354
9Section 03, Oxana Beskrovnaya OPTIONDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r15 · c32 · span 1133176–1133183
10Section 03, John Cox OPTIONDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r5 · c32 · span 1005521–1005528
11Section 03, Erick Lucera OPTIONDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r5 · c13 · span 831860–831869
12Section 03, Douglas Kerr OPTIONDEF 14A2026-04-230001193125-26-173655Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r12 · c32 · span 1094814–1094821
13Section 07, pay ratioDEF 14A2026-04-230001193125-26-173655Section “CEO Pay Ratio”. As printed: 6 : 1. Filing ↗machine: span 1763395–1763398
14Section 08, Vikram KarnaniDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 798,986. Filing ↗machine: t3 · r6 · c11 · span 369656–369663
15Section 08, Brian S. PosnerDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 571,159. Filing ↗machine: t3 · r9 · c15 · span 389985–389992
16Section 08, Jason RhodesDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 354,506. Filing ↗machine: t3 · r3 · c15 · span 352228–352235
17Section 08, Dirk KerstenDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 334,506. Filing ↗machine: t3 · r7 · c15 · span 377400–377407
18Section 08, David LubnerDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 334,506. Filing ↗machine: t3 · r8 · c15 · span 383689–383696
19Section 08, Catherine Stehman-Breen, M.DDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 327,006. Filing ↗machine: t3 · r10 · c15 · span 396291–396298
20Section 08, Edward HurwitzDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 317,006. Filing ↗machine: t3 · r4 · c15 · span 358519–358526
21Section 08, Carlo Incerti, M.DDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 317,006. Filing ↗machine: t3 · r5 · c15 · span 364815–364822
22Section 08, John G. CoxDEF 14A2026-04-230001193125-26-173655Section “Director Compensation”. As printed: 0. Filing ↗
23Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jason Rhodes 2026-04-23Form 42026-04-270001577014-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, David Lubner 2026-04-24Form 42026-04-280001193125-26-187601Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Jason Rhodes 2026-04-28Form 42026-04-300001577014-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Jason Rhodes 2026-05-04Form 42026-05-060001577014-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, John Cox 2026-05-13Form 42026-05-140001193125-26-223955Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Erick Lucera 2026-05-13Form 42026-05-140001193125-26-223961Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Johanna Friedl-Naderer 2026-05-13Form 42026-05-140001193125-26-223984Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Douglas Kerr 2026-05-13Form 42026-05-140001193125-26-223966Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Brian S. Posner 2026-05-20Form 42026-05-220001193125-26-236877Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Brian S. Posner 2026-05-26Form 42026-05-280001193125-26-245237Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Brian S. Posner 2026-06-03Form 42026-06-050001193125-26-259563Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Dirk Kersten 2026-06-05Form 42026-06-090001193125-26-264021Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Edward Hurwitz 2026-06-05Form 42026-06-090001193125-26-264031Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, David Lubner 2026-06-05Form 42026-06-090001193125-26-264025Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Jason Rhodes 2026-06-05Form 42026-06-090001193125-26-264022Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Brian S. Posner 2026-06-05Form 42026-06-090001193125-26-264004Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Catherine Stehman-Breen 2026-06-05Form 42026-06-090001193125-26-264011Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Carlo Incerti 2026-06-05Form 42026-06-090001193125-26-264019Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Brian S. Posner 2026-06-05Form 42026-06-090001193125-26-264004Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Douglas Kerr 2026-06-16Form 42026-06-170001814189-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Johanna Friedl-Naderer 2026-06-16Form 42026-06-170001915598-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, John Cox 2026-06-16Form 42026-06-170001498428-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Dirk Kersten 2026-06-17Form 42026-06-220001193125-26-277529Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Dirk Kersten 2026-06-17Form 42026-06-220001193125-26-277529Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Dirk Kersten 2026-06-22Form 42026-06-240001193125-26-281119Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Barry E. Greene 2026-06-22Form 42026-06-230001291963-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Dirk Kersten 2026-06-22Form 42026-06-240001193125-26-281119Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Dirk Kersten 2026-06-22Form 42026-06-240001193125-26-281119Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Jason Rhodes 2026-06-23Form 42026-06-260001577014-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Erick Lucera 2026-06-25Form 42026-06-260001193125-26-285505Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Jason Rhodes 2026-06-26Form 42026-06-300001577014-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Jason Rhodes 2026-07-06Form 42026-07-080001577014-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Dirk Kersten 2026-07-27Form 42026-07-290001193125-26-323754Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Dirk Kersten 2026-07-27Form 42026-07-290001193125-26-323754Insider equity transaction reported since the proxy statement. Filing ↗
108Section 06, 2026 voteForm 8-K2026-06-080001193125-26-261696Item 5.07 · say-on-pay result. As reported: 99.14% (votes for as printed: 147,732,142). Filing ↗
109Section 06, 2025 voteForm 8-K2025-06-050000950170-25-082317Item 5.07 · say-on-pay result. As reported: 82.47% (votes for as printed: 74,412,453). Filing ↗
110Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
111Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
112Section 09b board cost (computed)ComputedcomputedCash 408,750 + equity 0 + all other 0 = 408,750, summed across the director compensation table rows.machine: formula: Σ = 408,750
113Arcellx, Section 10b CEO totalDEF 14A2025-04-170001193125-25-084363CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897
114Immunovant, Section 10b CEO totalDEF 14A2026-07-220001764013-26-000092CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726
115BridgeBio Pharma, Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
116Revolution Medicines, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182453CEO total compensation as printed in Revolution Medicines's own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618
117Cytokinetics, Section 10b CEO totalDEF 14A2026-04-170001140361-26-015364CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103
118Crinetics Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-290001658247-26-000030CEO total compensation as printed in Crinetics Pharmaceuticals's own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460
119Nuvalent, Section 10b CEO totalDEF 14A2026-04-280001861560-26-000013CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247
120IDEAYA Biosciences, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191501CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319
121Xenon Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-220001193125-26-170320CEO total compensation as printed in Xenon Pharmaceuticals's own proxy. As printed: 9,221,712. Filing ↗machine: r2 · c28 · span 968086–968095
122Kymera Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191495CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146
123CRISPR Therapeutics AG, Section 10b CEO totalDEF 14A2026-04-210001193125-26-165158CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: t21 · r2 · c26 · span 821649–821658
124Arvinas, Section 10b CEO totalDEF 14A2026-04-290001628280-26-028156CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930
125Beam Therapeutics, Section 10b CEO totalDEF 14A2026-04-170001193125-26-161512CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178
126Celldex Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001104659-26-050884CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866
127Intellia Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001193125-26-197283CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299
128Denali Therapeutics, Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
129Rocket Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-060001140361-26-013335CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. Filing ↗machine: r2 · c24 · span 348766–348775
130Keros Therapeutics, Section 10b CEO totalDEF 14A2026-04-220001104659-26-046791CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989
131Dyne Therapeutics, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-230001193125-26-173655CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248
132Section 10a, Keros Therapeutics reciprocityDEF 14A0001104659-26-046791Keros Therapeutics's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
133Section 10a, Arcellx reciprocityDEF 14A0001193125-25-084363Arcellx's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
134Section 10a, Arvinas reciprocityDEF 14A0001628280-26-028156Arvinas's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
135Section 10a, Beam Therapeutics reciprocityDEF 14A0001193125-26-161512Beam Therapeutics's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
136Section 10a, CRISPR Therapeutics AG reciprocityDEF 14A0001193125-26-165158CRISPR Therapeutics AG names Dyne Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
137Section 10a, Revolution Medicines reciprocityDEF 14A0001193125-26-182453Revolution Medicines's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
138Section 10a, Denali Therapeutics reciprocityDEF 14A0001714899-26-000054Denali Therapeutics names Dyne Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
139Section 10a, Intellia Therapeutics reciprocityDEF 14A0001193125-26-197283Intellia Therapeutics's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
140Section 10a, Crinetics Pharmaceuticals reciprocityDEF 14A0001658247-26-000030Crinetics Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
141Section 10a, Cytokinetics reciprocityDEF 14A0001140361-26-015364Cytokinetics's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
142Section 10a, Kymera Therapeutics reciprocityDEF 14A0001193125-26-191495Kymera Therapeutics names Dyne Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
143Section 10a, Nuvalent reciprocityDEF 14A0001861560-26-000013Nuvalent's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
144Section 10a, IDEAYA Biosciences reciprocityDEF 14A0001193125-26-191501IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
145Section 10a, Immunovant reciprocityDEF 14A0001764013-26-000092Immunovant's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
146Section 10a, Xenon Pharmaceuticals reciprocityDEF 14A0001193125-26-170320Xenon Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
147Section 10a, Celldex Therapeutics reciprocityDEF 14A0001104659-26-050884Celldex Therapeutics's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗
148Section 10a, BridgeBio Pharma reciprocityDEF 14A0001140361-26-016723BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Dyne Therapeutics, Inc.. Filing ↗